Cargando…

BRCA1 and BRCA2 screening of nine Chilean founder mutations through allelic-discrimination and real-time PCR in breast/ovarian cancer patients

BACKGROUND: In a previous work, we identified nine founder mutations present in close to 80% of BRCA1 and BRCA2 mutation carriers, and distributed across the country. The presence of founder mutations constitutes a valuable opportunity to develop new strategies for genetic screening. Genetic tests a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarez, Carolina, Ortega-Hernández, Victoria, Cortez, Aracely, Carvallo, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123627/ https://www.ncbi.nlm.nih.gov/pubmed/35596815 http://dx.doi.org/10.1007/s11033-022-07561-4

Ejemplares similares

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
por: Alvarez, Carolina, et al.
Publicado: (2017)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

A Founder Mutation of the BRCA1-Gene in Western Sweden
por: Einbeigi, Zakaria, et al.
Publicado: (1999)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients
por: Fragoso-Ontiveros, Veronica, et al.
Publicado: (2019)

Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
por: Janavičius, Ramūnas
Publicado: (2010)

Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa
por: ElBiad, Oubaida, et al.
Publicado: (2022)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1
por: Caleca, Laura, et al.
Publicado: (2014)

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects
por: Jervis, Sarah, et al.
Publicado: (2015)

Advanced topics in BRCA1/BRCA2 analysis by genetic analyzer and real-time PCR
por: Rassi, H
Publicado: (2009)

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
por: Gallardo-Rincón, Dolores, et al.
Publicado: (2022)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2021)

Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G
por: Claes, Kathleen, et al.
Publicado: (1999)

The Icelandic founder mutation BRCA2 999del5: analysis of expression
por: Mikaelsdottir, Evgenia K, et al.
Publicado: (2004)

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study
por: Kowalik, Artur, et al.
Publicado: (2018)

Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank
por: Abul-Husn, Noura S., et al.
Publicado: (2019)

Non-BRCA1/2 Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer
por: Adaniel, Christina, et al.
Publicado: (2019)

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
por: Kuusisto, Kirsi M, et al.
Publicado: (2011)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective
por: Dutil, Julie, et al.
Publicado: (2015)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
por: Li, Jun, et al.
Publicado: (2022)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia
por: Tuazon, Anna Marie De Asis, et al.
Publicado: (2020)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3pu9f7h6m6k0letu912ejfpf4i